 |
Find a Stock's Home Page |
|
| News |
San Diego, CA Jul 08, 2009
The Small Cap Network (smallcapnetwork.com), a leading online investment community focused on small cap companies, has issued comments regarding yesterday's letter to shareholders from CEL-SCI Corp. (AMEX:CVM) CEO Geert Kersten.
The CEO's letter discusses the failure of Tamiflu to effectively treat a handful of swine flu cases, which is a problem that could get worse of the current strain of swine flu swaps genes with the a flu strain commonly called 'bird flu'. If the few cases where Tamiflu was ineffective was the result of a mutated virus gene, the need for an 'adaptive' flu treatment becomes clear. CEL-SCI's L.E.A.P.S. technology may well be such an adaptive treatment.
The newsletter's editors examine the revenue created by sales of Tamiflu (and Relenza) just from the swine flu scare alone. If Tamiflu and Relenza become completely ineffective against a new, mutated strain of swine flu, CEL-SCI could be positioned to benefit from the search for al alternative treatment.
Investors and traders are invited to learn more about Generex Biotechnology by subscribing to the free Small Cap Network Newsletter, which offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: http:// access.smallcapnetwork.com/t/ CEL-SCI Corporation
About
CEL-SCI Corporation (AMEX:CVM) is developing products that empower immune defenses. Its lead product is Multikine(r) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
TGR Group LLC has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.
Contact Information: Small Cap Network 4653 Carmel Mtn. Rd Suite 308 #402 San Diego, CA 92130 Email: editor@smallcapnetwork.com
Source: Small Cap Network
CONTACT: Small Cap Network e-mail: editor@smallcapnetwork.com
